-
Revisiting Medicine 3.0
In this month’s issue, we continue the exploration of Medicine 3.0, the next-generation of cutting-edge practices that patients need to adopt if we wish to maximize our healthspan as well as our lifespan. By being proactive, informed, and by taking concrete action, Erez Kalir writes, we can add both years to our lives, and life to our years.
-
Update: SharpLink Gaming (SBET) and GDS Holdings (GDS)
This coming January will mark two years since we launched Tech Frontiers and its predecessor, Biotech Frontiers. During that time, we’ve compiled an extraordinary track record: Eight of our recommendations have appreciated over 100% and many others have appreciated at least 50%. In the meantime, in our biotech portfolio, we encountered only two meaningful losers
-
China’s AI Landlord
China’s artificial intelligence sector is not in a market bubble. In fact, the company Erez Kalir recommends this month trades at a significantly lower valuation than its U.S. peers and is poised to soar going forward.
-
A Piggybank For Ethereum
If you’ve missed out on Bitcoin’s and Ethereum’s meteoric rise, this month’s issue of Tech Frontiers is for you. If you’ve ridden these meteors, congratulations – this issue will offer you a thoughtful way to diversify your gains and stay onboard.
-
Sell Alert: Half Position Of Prime Medicine
Shares of the Tech Frontiers July recommendation, Prime Medicine (Nasdaq: PRME), are trading at around $6.37 today, a gain of over 100% from our entry price of $3.07 three months ago. As a result, we recommend selling half your position. Prime is making terrific progress advancing its gene-editing platform and we have many reasons for